2014
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimer's Research & Therapy 2014, 6: 8. PMID: 24495408, PMCID: PMC3978417, DOI: 10.1186/alzrt238.Peer-Reviewed Original ResearchAlzheimer's diseasePathogenesis of ADTreatment of ADPhase Ib studyLate-stage clinical testingUnique therapeutic targetMajor pathologic hallmarkDevastating neurodegenerative disorderPathologic hallmarkNovel therapiesIb studyTherapeutic strategiesTherapeutic targetSmall molecule inhibitorsClinical testingTyrosine kinase FynCellular prion proteinNeurodegenerative disordersDiseaseAβ oligomersCell surface bindingMultisite studyHigh potencyMolecule inhibitorsTherapy
2009
Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers: Implications for Alzheimer Disease
Nygaard HB, Strittmatter SM. Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers: Implications for Alzheimer Disease. JAMA Neurology 2009, 66: 1325-1328. PMID: 19901162, PMCID: PMC2849161, DOI: 10.1001/archneurol.2009.223.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseCellular prion proteinPathogenesis of ADBeta-amyloid plaquesAge-related dementiaSoluble oligomeric assembliesPrion proteinPotential clinical implicationsBeta-amyloid oligomersΒ-amyloid oligomersHigh-affinity receptorCommon causeSynaptic plasticityTherapeutic interventionsClinical implicationsAbeta oligomersNovel targetRecent evidenceToxic effectsDiseasePathogenesisDementiaAbetaPlaquesBrain